AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00187-07v1
51/5/1885    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rantala, M.
Right arrow Articles by Kaijalainen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rantala, M.
Right arrow Articles by Kaijalainen, T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2007, p. 1885-1887, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.00187-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Molecular Epidemiology of Telithromycin-Resistant Pneumococci in Finland{triangledown}


   LETTER
Top
 LETTER
REFERENCES
 
In our previous study, we described 26 clinical pneumococci with heterogeneous resistance to telithromycin (TEL). In this resistance type, separate colonies grew inside the inhibition zone around the TEL disk in a disk diffusion test (8). In this study we investigated the molecular epidemiology of these 26 isolates and compared them to erm(B)-positive but TEL-susceptible (Tels) pneumococci (n = 66) (9). Published methods were used for antimicrobial susceptibility testing (7), serotyping (3), pulsed-field gel electrophoresis (PFGE) typing (5, 4), and multilocus sequence typing (MLST) (1). PFGE was performed for all TEL-resistant (Telr) isolates, for 3 zone isolates (8), and for 22 randomly selected Tels, erm(B)-positive isolates, but MLST typing and serotyping were performed only for Telr isolates. Our results were compared to international databases (www.mlst.net and www.sph.emory.edu/PMEN).

The clinical characteristics, antimicrobial susceptibilities, PFGE profiles, and sequence types (STs) of the isolates are summarized in Table 1. Penicillin nonsusceptibility (MIC of ≥0.125 µg/ml) was less frequent among erm(B)-positive Telr isolates (4/26) than among erm(B)-positive Tels isolates (50/66) (P < 0.0001, Fisher's exact test). The same applied to penicillin and tetracycline coresistance. None of the isolates was resistant to levofloxacin or linezolid. The most frequent serotype was 19A. Telr isolates were distributed among 7 distinct PFGE types, of which type A was the most frequent with 19 isolates. Tels erm(B) isolates had more heterogeneous PFGE patterns, since 12 different PFGE types were detected among 22 Tels isolates (Fig. 1).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Summary of clinical and molecular data for 26 clinical pneumococcal isolates with heterogeneous resistance to telithromycin

 

Figure 1
View larger version (27K):
[in this window]
[in a new window]

  		FIG. 1. Dendrogram and PFGE patterns of 26 Telr, erm(B)-positive pneumococci. Telr isolates are in boldface. Respective patterns of 22 erm(B)-positive but Tels isolates are also presented. Three isolates designated with the letter V are zone isolates (isolates derived from colonies which grew inside the inhibition zone around the TEL disk in the disk diffusion test) with a pattern identical to those of their parent isolates, 547, 415, and 1022. The dotted line defines PFGE profiles with ≥85% similarity (unweighted-pair group method using average linkages, Dice; black vertical dotted line).

 
MLST types 193, 271, and 273, found among our isolates, are representatives of global pneumococcal clones. ST 193 belongs to the pneumococcal global clone Greece21-30, which has been found in Greece, Brazil, the United Kingdom, and Vietnam (12, 13). The clone was reported to be penicillin susceptible but otherwise multidrug resistant, which also applies to our isolates. ST 273 is a representative of the penicillin-susceptible but erythromycin-resistant PMEN clone, Greece6B-22. Apart from Greece, this clone has been detected in Iceland, Israel, Portugal, Italy, Germany, and Switzerland (6, 11). ST 133 has been detected in Spain (www.mlst.net). ST 271 is a single-locus variant of a multidrug-resistant Taiwanese 19F clone, ST 236 (10). In one international study, ST 271 was detected worldwide and more than 85% of pneumococcal isolates with a double resistance mechanism, erm(B) and mef(E), belonged to this clonal complex (2). Our ST 271 isolate also had a double resistance mechanism. The other isolate in this study with a double mechanism had a novel ST, ST 2248. Two additional new MLST types were detected: ST 2306 and ST 2307.

The presence of more than one PFGE and MLST type among Telr isolates suggests that the capability for expressing TEL resistance has arisen several times in S. pneumoniae. It is also likely that TEL resistance is an older phenomenon and would not have been caused by TEL selection pressure, because all of our strains were collected in 2002, just before TEL was introduced into clinical practice in Finland. The fact that all of our isolates were of clinical origin means that this type of resistance can survive in the bacterial population and cause diseases to humans. It is also noticeable that six of these isolates were from invasive infections. Our results indicate that pneumococci with heterogeneous TEL resistance can be found in other countries, because many of our strains belonged to global clones. However, this resistance type is difficult to detect using the dilution method (8). We recommend that routine testing of TEL susceptibility of pneumococci be done with the disc diffusion method in a 5%-CO2 atmosphere, especially in areas where erm(B) is a common resistance mechanism.


   ACKNOWLEDGMENTS
 
We thank Bruno Pichon from the Health Protection Agency, London, England, for advice in setting up the MLST typing method in our laboratory. We also thank the FiRe laboratory network (Finnish Study Group for Antimicrobial Resistance) (www.ktl.fi/extras/fire) for sending the isolates and Mari Virta and Erkki Nieminen for their excellent technical assistance.


   FOOTNOTES
 
{triangledown} Published ahead of print on 26 February 2007. Back


   REFERENCES
Top
 LETTER
 REFERENCES
 

  1. Enright, M. C., and B. G. Spratt. 1998. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology 144:3049-3060.[Abstract]
  2. Farrell, D. J., I. Morrissey, S. Bakker, L. Morris, S. Buckridge, and D. Felmingham. 2004. Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J. Clin. Microbiol. 42:764-768.[Abstract/Free Full Text]
  3. Henrichsen, J., E. Berntsson, and B. Kaijser. 1980. Comparison of counterimmunoelectrophoresis and the capsular reaction test for typing of pneumococci. J. Clin. Microbiol. 11:589-592.[Abstract/Free Full Text]
  4. Lefevre, J. C., G. Faucon, A. M. Sicard, and A. M. Gasc. 1993. DNA fingerprinting of Streptococcus pneumoniae strains by pulsed-field gel electrophoresis. J. Clin. Microbiol. 31:2724-2728.[Abstract/Free Full Text]
  5. Matushek, M. G., M. J. Bonten, and M. K. Hayden. 1996. Rapid preparation of bacterial DNA for pulsed-field gel electrophoresis. J. Clin. Microbiol. 34:2598-2600.[Abstract]
  6. Munoz, R., T. J. Coffey, M. Daniels, C. G. Dowson, G. Laible, J. Casal, R. Hakenbeck, M. Jacobs, J. M. Musser, B. G. Spratt, et al. 1991. Intercontinental spread of a multiresistant clone of serotype 23F Streptococcus pneumoniae. J. Infect. Dis. 164:302-306.[Medline]
  7. Pihlajamaki, M., T. Kaijalainen, P. Huovinen, and J. Jalava. 2002. Rapid increase in macrolide resistance among penicillin non-susceptible pneumococci in Finland, 1996-2000. J. Antimicrob. Chemother. 49:785-792.[Abstract/Free Full Text]
  8. Rantala, M., M. Haanpera-Heikkinen, M. Lindgren, H. Seppala, P. Huovinen, and J. Jalava. 2006. Streptococcus pneumoniae isolates resistant to telithromycin. Antimicrob. Agents Chemother. 50:1855-1858.[Abstract/Free Full Text]
  9. Rantala, M., S. Huikko, P. Huovinen, and J. Jalava. 2005. Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002. Antimicrob. Agents Chemother. 49:4180-4184.[Abstract/Free Full Text]
  10. Shi, Z. Y., M. C. Enright, P. Wilkinson, D. Griffiths, and B. G. Spratt. 1998. Identification of three major clones of multiply antibiotic-resistant Streptococcus pneumoniae in Taiwanese hospitals by multilocus sequence typing. J. Clin. Microbiol. 36:3514-3519.[Abstract/Free Full Text]
  11. Sousa, N. G., R. Sa-Leao, M. I. Crisostomo, C. Simas, S. Nunes, N. Frazao, J. A. Carrico, R. Mato, I. Santos-Sanches, and H. de Lencastre. 2005. Properties of novel international drug-resistant pneumococcal clones identified in day-care centers of Lisbon, Portugal. J. Clin. Microbiol. 43:4696-4703.[Abstract/Free Full Text]
  12. Syrogiannopoulos, G. A., I. N. Grivea, N. G. Beratis, A. E. Spiliopoulou, E. L. Fasola, S. Bajaksouzian, P. C. Appelbaum, and M. R. Jacobs. 1997. Resistance patterns of Streptococcus pneumoniae from carriers attending day-care centers in southwestern Greece. Clin. Infect. Dis. 25:188-194.[Medline]
  13. Syrogiannopoulos, G. A., F. Ronchetti, R. Dagan, I. Grivea, M. P. Ronchetti, N. Porat, T. A. Davies, R. Ronchetti, P. C. Appelbaum, and M. R. Jacobs. 2000. Mediterranean clone of penicillin-susceptible, multidrug-resistant se-rotype 6B Streptococcus pneumoniae in Greece, Italy and Israel. Int. J. Antimicrob. Agents 16:219-224.[CrossRef][Medline]
Merja Rantala*
Sofia Nyberg
Marianne Lindgren
Pentti Huovinen
Jari Jalava
Department of Bacterial and Inflammatory Diseases
National Public Health Institute
Kiinamyllynkatu 13
FIN-20520 Turku, Finland

Reetta Skyttä
Laura Teirilä
Anni Vainio
Anni Virolainen-Julkunen
Department of Bacterial and Inflammatory Diseases
National Public Health Institute
Helsinki, Finland

Tarja Kaijalainen
Laboratory for Chlamydia and Respiratory Tract Bacteria
National Public Health Institute
Oulu, Finland

* Phone: 358-2-331 6629, Fax: 358-2-331 6699, E-mail: merja.rantala{at}ktl.fi

Antimicrobial Agents and Chemotherapy, May 2007, p. 1885-1887, Vol. 51, No. 5
0066-4804/07/$08.00+0     doi:10.1128/AAC.00187-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
AAC.00187-07v1
51/5/1885    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rantala, M.
Right arrow Articles by Kaijalainen, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rantala, M.
Right arrow Articles by Kaijalainen, T.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS